Nohla Therapeutics
Founder Colleen Delaney and CEO Kathleen Fanning
Country: USA | Funding: $120.5M (+)
Nohla Therapeutics is a developing an shelf alternative to bone marrow transplants. Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. Permanently closed
Nohla Therapeutics is a developing an shelf alternative to bone marrow transplants. Nohla is leading the development of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases. Permanently closed
